Boston Scientific launches U.S. Parkinson's trial, cites interim EU data

June 18, 2013 by Brad Perriello

Boston Scientific launches a U.S. clinical trial of its Vercise deep-brain stimulation treatment for Parkinson's disease and touts interim data from a European trial of the device.

Boston Scientific launches U.S. Parkinson's trial, cites interim EU data

Boston Scientific (NYSE:BSX) said it launched a U.S. clinical trial of its Vercise deep-brain stimulation treatment for patients with Parkinson's disease and touted interim results from a European study of the device.

The Natick, Mass.-based medical device company said the Intrepid trial is designed to evaluate the safety and efficacy of the device in improving motor function and quality of life for patients with the neurological condition. The 1st patient in the trial received the device at Cedars-Sinai hospital in Los Angeles.

The Vercise device has CE Mark approval in the European Union and won a nod from Australia's Therapeutic Goods Administration, according to a press release. BSX touts the device as the only DBS system with adjustable current flow to allow doctors to manipulate the current in "fine increments," according to the release.

Sign up to get our free newsletters delivered straight to your inbox

In a separate statement, Boston Scientific said interim results from a European trial of the Vercise device showed "a significant improvement in motor scores" in data presented at the International Congress of Parkinson's Disease & Movement Disorders in Sydney.

Comments